conditional

School-age children and adolescents (5 to 19 years),
and adults, including lactating women, with active
TB and moderate undernutrition, who fail to
regain normal body mass index after 2 months of TB
treatment, as well as those who are losing weight
during TB treatment, should be evaluated for
adherence and comorbid conditions. They should
also receive nutrition assessment and counselling
and, if indicated, be provided with locally available
nutrient-rich or fortified supplementary foods as

In settings where contact tracing is implemented,
household contacts of people with active TB should
have a nutrition screening and assessment as part of
contact investigation. If malnutrition is identified,
it should be managed according to WHO
recommendations.

All lactating women with active TB should be
provided with iron and folic acid and other
vitamins and minerals, according to the United
Nations Multiple Micronutrient Preparation, to
complement their maternal micronutrient needs.

(a) Systematic screening for active TB may be considered for geographically
defined subpopulations with extremely high levels of undetected TB (1%
prevalence or higher).
(b) Systematic screening for active TB may be considered also for other
subpopulations that have very poor access to health care, such as people
living in urban slums, homeless people, people living in remote areas with
poor access to health care, and other vulnerable or marginalized groups
including some indigenous populations, migrants and refugees.

In settings where the TB prevalence in the general
population is 100/100 000 population or higher, systematic screening for
active TB should be considered among people who are seeking health care or
who are in health care and who belong to selected risk groups.

Systematic screening for active TB should be considered
in people with an untreated fibrotic chest X-ray lesion.

Systematic screening for active TB should be considered
in prisons and other penitentiary institutions.

Adults and adolescents living with HIV who have an unknown or positive TST status and who are
unlikely to have active TB should receive at least 36 months of IPT. IPT should be given to such
individuals irrespective of the degree of immunosuppression, and also those on ART, those who
have previously been treated for TB and pregnant women.

All children living with HIV after successful completion of treatment for TB disease should receive
isoniazid for an additional 6 months.

During the continuation phase of treatment, thrice-weekly regimens can be considered
for children known to be HIV-uninfected living in settings with well-established
directly-observed therapy (DOT).